Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age

Acronyms

Acronyms used throughout the guideline

25-OH D 25-hydroxyvitamin D
AAOMS American Association of Oral and Maxillofacial Surgeons
ADA American Dental Association
ADT androgen deprivation therapy
AFF atypical fracture of the femur
AI aromatase inhibitor
ARR absolute risk reduction
BMD bone mineral density
BMI body mass index
BP blood pressure
CEE conjugated equine (o)estrogen
CI confidence interval
CTX C-terminal telopeptide
CV cardiovascular
DXA dual energy X-ray absorptiometry
EMA European Medicines Agency
ER (o)estrogen receptor
FN femoral neck
FRAX Fracture Risk Assessment Too
GFRC Garvan Fracture Risk Calculator
GIT gastrointestinal
GnRH gonadotropin-releasing hormone
GP general practitioner
HIV human immunodeficiency virus
hPTH human parathyroid hormone
HR hazard ratio
HT hormone therapy
IV intravenous
MA meta-analysis
MI myocardial infarction
MRONJ medication-related osteonecrosis of the jaw
NHMRC The National Health and Medical Research Council
NNT number need to treat
OR odds ratio
PBS Pharmaceutical Benefits Scheme
PINP procollagen type 1 amino-terminal propeptide
PPI proton pump inhibitor
PTH parathyroid hormone
QALY quality-adjusted life year
QCT quantitative computed tomography
QUS quantitative ultrasound
RACGP The Royal Australian College of General Practitioners
RANKL receptor activator of nuclear factor kappa B ligand
RaR rate ratio
RCT randomised controlled trial
RDI recommended dietary intake
RR relative risk
SD standard deviation
SERMs selective oestrogen receptor modulators
SFP secondary fracture prevention
SR systematic review
SSRI selective serotonin reuptake inhibitor
TUG timed up and go
WHI Women’s Health Initiative
WHO World Health Organization

Related documents

  Osteoporosis-flowchart.pdf (PDF 0.98 MB)